# Trial of Pembrolizumab in Cancer of Unknown Primary

> **NCT03752333** · PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 35 (actual)

## Conditions studied

- Cancer of Unknown Primary Site

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03752333
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-22
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03752333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03752333, "Trial of Pembrolizumab in Cancer of Unknown Primary". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03752333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*